| Name: | Jeffrey A. Moscow |
| Position Type: | Chair |
| Appointment Start Date: | 07/01/03 |
| Appointment End Date: | 06/30/08 |
| Area of Specialty: | Pediatric hematology-oncology Experimental therapeutics in oncology |
| Summary Vita: | Professor of Pediatrics Chief, Division of Pediatric Hematology-Oncology Director, Experimental Therapeutics Program, Markey Cancer Center Director, University of Kentucky Hemophilia Treatment Center |
| Highest Degree: | M.D. |
| Professional Affiliations: | Affiliations: American Association for Cancer Research American Society for Pediatric Hematology/Oncology American Academy of Pediatrics Lexington Medical Society American Society for Clinical Oncology Kentucky Medical Association Regional Committees: Medical Advisory Board, Kentucky Commission for Children with Special Health Care Needs Board of Directors, Friends of Indian Summer (summer camp for children with cancer) National Committees: Children's Oncology Group acute myelogeous leukemia relapse committee |
| Primary Research Focus: | Develop novel approaches to the treatment of cancer by targeting changes in expression of proteins involved in the uptake of nutrients into cancer cells |
| Key Contributions: | Identification of changes in nutrient transporters in human cancers. |
| Publications: | Liu, S., Stromberg, A., Tai H-H. and Moscow, J.A. Thiamine transporter gene expression and exogenous thiamine modulate expression of genes potentially involved in oncogenesis in breast cancer. Molecular Cancer Research, 2, 477-487, 2004. Griffin, T.C., Hutter, J.J., Johnson, K.K. and Moscow, J.A. Clinical productivity and current procedural terminology (CPT) coding patterns of pediatric hematologist/oncologists. Pediatric Blood and Cancer, 43: 1-8, 2004. Wong, E.C.C, Perez-Albuerne, E., Moscow, J.A., and Luban, N.L.C. Transfusion management strategies: A survey of practicing pediatric hematology-oncology specialists. Pediatric Blood and Cancer, 44, 119-127, 2005. Ding, Y., Tong, M., Liu, S., Moscow, J.A., and Tai, H-H. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor gene in lung cancer. Carcinogenesis, 26, 65-72, 2005. Moscow, J.A., Schneider, E., Sikic, B.I., Morrow, C.S., and Cowan K.H. "Drug resistance and its clinical circumvention" In Kufe, D.W., Bast, R.C., Pollock, R., Weichselbaum, R.R., Holland, J.F, and Frei, E. III ed., Cancer Medicine, seventh edition, Brian C. Decker, Hamilton, Ontario, in press. |